Compliance begets efficacy

Cytos Biotechnology AG hopes that its CYT006-AngQb, a therapeutic vaccine against angiotensin II, may one day offer an attractive antihypertensive alternative to ARBs, ACE inhibitors and renin inhibitors, as it targets the same pathway and may need to be given only twice a year after initial loading doses.

The company released Phase IIa data last month showing that the vaccine reduced systolic and diastolic blood pressure, although the reductions were

Read the full 701 word article

How to gain access

Continue reading with a
two-week free trial.